【活動快訊】Aaron Ciechanover 教授（2004諾貝爾化學獎得主）醫藥通俗演講

以色列教授 Aaron Ciechanover （2004諾貝爾化學獎）應王光燦基金會邀請，將於11月6日（星期五）拜訪臺灣大學，下午3:30在化學系松柏講堂做通俗科學演講。

講題：The Revolution of Personalized Medicine: Are We Going to Cure All Diseases and at What Price?

Prof. Aaron Ciechanover

• Born October 1, 1947.
• The Nobel Prize in Chemistry 2004 was awarded jointly to Aaron Ciechanover, Avram Hershko and Irwin Rose "for the discovery of ubiquitin-mediated protein degradation". The ubiquitin-proteasome pathway has a critical role in maintaining the homeostasis of cells and is believed to be involved in the development and progression of diseases such as: cancer, muscular and neurological diseases, immune and inflammatory responses.
• 2015 王光燦生物有機化學講座

Biography

He received his doctorate in biochemistry in 1981 from the Technion – Israel Institute of Technology in Haifa before conducting postdoctoral research in the laboratory of Harvey Lodish at the Whitehead Institute at MIT from 1981-1984. He is currently a Technion Distinguished Research Professor in the Ruth and Bruce Rappaport Faculty of Medicine and Research Institute at the Technion.

Awards

• Albert Lasker Award for Basic Medical Research, 2000.
• Israel Prize, for Biology, 2003.
• Nobel Prize in Chemistry, 2004.
• Sir Hans Krebs Medal, 2006.

Member of Scientific Advisory Boards

• Rosetta Genomics (Chairman)
• BioLineRx, Ltd
• StemRad, Ltd
• Allosterix Ltd
• Proteologics, Inc
• MultiGene Vascular Systems, Ltd
• Protalix BioTherapeutics
• BioTheryX, Inc.
• Patient Innovation, a nonprofit, international, multilingual, free venue for patients and caregivers of any disease to share their innovations.